CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

Despite weak Q3 earnings, Bharat Petroleum (BPCL) draws attention from global brokerages. CLSA upgraded BPCL to ‘Hold’ with a ...

Shares of UltraTech Cement Ltd. fell on Friday despite the third quarter numbers being slightly ahead of expectations.

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Brokerage firm Nuvama has highlighted concerns about BPCL's weak refining margin environment and LPG under-recoveries, which are impacting its earnings. Additionally, the high capital expenditure ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

Vikash Kumar Jain, India Strategist and Head of Research at CLSA, predicts 2025 will be a year of consolidation for Indian markets. He noted that the consolidation trend, which began in October, could ...

In a report released on January 21, Garry Sherriff from RBC Capital maintained a Hold rating on Pro Medicus Limited (PMCUF – Research Report), ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

CLSA has initiated coverage on Hyundai Motor India with an 'Outperform' rating and a target price of Rs 2,155, citing strong ...

In a report released today, Adrian Lemme from Citi maintained a Buy rating on Coles Group Ltd. (CLEGF – Research Report), with a price target ...